Erytech Pharma SA (EPA: ERYP) has appointed Alex Dusek as vice president of commercial strategy and member of the executive team, the biopharmaceutical company disclosed on Monday.
Dusek has 25 years of market access, product marketing and sales experience across small biotech start-ups and multi-national pharmaceutical companies.
Before joining Erytech, Dusek served as vice president of commercial strategy at Argos Therapeutics (OTCMKTS: ARGS). There he was responsible for pre-launch planning for the commercial distribution of an advanced cell therapy product.
His previous roles included leading global brand strategy at Bayer HealthCare Pharmaceuticals (ETR: BAYN) for the launch of a first-in-class, rare-disease agent, Adempas (riociguat). He was also United Therapeutics' (NASDAQ: UTHR) first marketing employee, building the company's marketing infrastructure and growing the pulmonary hypertension franchise.
Dusek will be based in the US, joining Erytech's expanding team in Cambridge, Massachusetts.
Santhera Pharmaceuticals signs Gulf region distribution agreement with Uniphar
Novo Nordisk expands legal action over compounded 'semaglutide'
Neuraxpharm launches Neuraxpharm Australia
OncoZenge selects Meribel Pharma as CDMO for Phase 3 BupiZenge project
Fridays nominated for World Out of Home awards for weight loss campaign
Physiomics expands into biometrics with two contract wins and new division head
DELFI Diagnostics CTO receives 2025 Most Influential Women in Bay Area Business recognition
Healthcare Holding Schweiz AG acquires Effectum CH-Rep AG to expand services
iOncologi acquires TargImmune Therapeutics
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'